<div id="readability-page-1"><p>Versant Venture Management LLC acquired a new position in  Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report) during the second quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund acquired 1,525,820 shares of the company's stock, valued at approximately $15,243,000. Jade Biosciences accounts for about  18.6% of Versant Venture Management LLC's portfolio, making the stock its 3rd biggest position. Versant Venture Management LLC owned about 181.43% of Jade Biosciences at the end of the most recent reporting period.</p><p>A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Police &amp; Firemen s Retirement System of New Jersey bought a new position in  Jade Biosciences during the 2nd quarter worth approximately $71,000.  Deltec Asset Management LLC bought a new stake in shares of  Jade Biosciences in the 2nd quarter valued at $157,000.  Intech Investment Management LLC acquired a new stake in shares of  Jade Biosciences during the second quarter worth $230,000.  Finally, Geode Capital Management LLC bought a new position in  Jade Biosciences during the second quarter worth $6,759,000. </p><div><p><span></span><span>Get <strong>Jade Biosciences</strong> alerts:</span></p></div><h2>Jade Biosciences Stock Up 0.5%</h2><p>Shares of NASDAQ JBIO opened at $12.65 on Wednesday. The firm's 50-day moving average is $9.11. Jade Biosciences, Inc. has a 1-year low of $6.57 and a 1-year high of $100.10. The firm has a market capitalization of $412.77 million, a price-to-earnings ratio of -1.13 and a beta of 1.07. </p><p>Jade Biosciences (NASDAQ:JBIO - Get Free Report) last issued its earnings results on Friday, November 14th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.09. </p><h2>Analysts Set New Price Targets</h2><p>A number of analysts have commented on the stock. Weiss Ratings  reaffirmed a &#34;sell (e)&#34; rating on shares of Jade Biosciences in a research report on Friday, October 31st. Guggenheim lifted their price objective on Jade Biosciences from $14.00 to $17.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Wall Street Zen upgraded Jade Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday. Wedbush raised their target price on Jade Biosciences from $17.00 to $18.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, August 14th. Finally, BTIG Research began coverage on Jade Biosciences in a research note on Thursday, October 9th. They issued a &#34;buy&#34; rating and a $28.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Jade Biosciences presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $19.75.</p><p><b>Check Out Our Latest Stock Report on JBIO</b></p><h2>Jade Biosciences Profile</h2> (Free Report)<p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p><h2>See Also</h2><ul><li>Five stocks we like better than Jade Biosciences</li><li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li><li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li><li>Why Invest in High-Yield Dividend Stocks?</li><li>Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum</li><li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li><li>What’s on the Thanksgiving Table? A Stock Pick for Every Course</li></ul><p><strong>Want to see what other hedge funds are holding JBIO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkJJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkJJTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Jade Biosciences Right Now?</h2><p>Before you consider Jade Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jade Biosciences wasn't on the list.</p><p>While Jade Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

JBIO

<p>Versant Venture Management LLC invested $15.24 million in Jade Biosciences, acquiring 1,525,820 shares, making it a significant part of their portfolio. Jade Biosciences' stock has a Moderate Buy rating, with analysts setting new price targets. The stock opened at $12.65, with a market cap of $412.77 million. Analysts have mixed ratings, with some upgrading their price targets. Jade Biosciences focuses on developing drugs for rare cardiopulmonary diseases.</p>

Versant Venture Management LLC Invests $15.24 Million in Jade Biosciences, Inc. $JBIO